Xu Diyong 4
4 · Q32 Bio Inc. · Filed Jun 1, 2026
Research Summary
AI-generated summary of this filing
Q32 Bio (QTTB) 10% Owner Xu Diyong Buys $15M in Private Placement
What Happened
- Xu Diyong, reported as a 10% owner of Q32 Bio, purchased a total of 1,875,000 shares of Q32 Bio common stock in a private placement on May 28, 2026. The purchases were made in two tranches: 1,250,000 shares and 625,000 shares, each at $8.00 per share, for a combined cash outlay of $15,000,000. This was a purchase (transaction code P) — a direct investment into the company rather than a sale.
Key Details
- Transaction date: May 28, 2026. Filing date: June 1, 2026 (Accession 0000947871-26-000594). Filing appears timely (filed within two business days).
- Prices and amounts: 1,250,000 shares @ $8.00 ($10,000,000) and 625,000 shares @ $8.00 ($5,000,000); total 1,875,000 shares for $15,000,000.
- Purchase type: Private placement (per footnote F1 — shares purchased from the issuer).
- Shares owned after transaction: Not specified in the excerpt provided (see the full Form 4 for post-transaction holdings).
- Other footnotes in the filing (F2–F4) concern OrbiMed-related entities and disclaimers of beneficial ownership for securities held by those funds; these relate to other reporting relationships in the filing and are not described as changing this purchase.
- Transaction code: P = Purchase.
Context
- This was a direct purchase from the company (private placement), which injects cash into Q32 Bio but is dilutive to existing shareholders since new shares were issued. Purchases by a 10% owner can signal an institutional/major investor increasing exposure, but filings are factual records — they do not explain motives.
- The filing met timing requirements based on the dates shown. For full post-transaction ownership and any additional disclosures, consult the complete Form 4 (Accession number above).
Insider Transaction Report
Form 4
Q32 Bio Inc.QTTB
Xu Diyong
Director10% Owner
Transactions
- Purchase
Common Stock
[F1][F2][F4]2026-05-28$8.00/sh+1,250,000$10,000,000→ 3,502,987 total(indirect: See footnotes) - Purchase
Common Stock
[F1][F3][F4]2026-05-28$8.00/sh+625,000$5,000,000→ 625,000 total(indirect: See footnotes)
Footnotes (4)
- [F1]These shares of the Issuer's common stock were purchased from the Issuer in a private placement.
- [F2]These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII.
- [F3]These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.
- [F4]Each of the Reporting Person, OrbiMed Advisors, OrbiMed GP, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Signature
/s/Diyong Xu|2026-06-01